Alimera Sciences Inc. promoted Richard Eiswirth Jr., who is also a president of the company, from CFO to CEO and named him to the board.
The executive change was made following the approval of a succession plan by Alimera's board that is intended to be effective Jan. 2.
Under the succession plan, C. Daniel Myers, co-founder of the company, retired as CEO and became a consultant to Alimera and nonexecutive board chairman.
Moreover, J. Philip Jones, the company's former vice president of finance, was appointed as CFO.
Philip Ashman, who was previously Alimera's senior vice president managing director Europe, was named as COO and senior vice president commercial operations Europe.
Alpharetta, Ga.-based Alimera Sciences is a pharmaceutical company, which engages in the research, development and commercialization of prescription ophthalmic, or eye-related, pharmaceuticals.